Abstract: Objective To evaluate the efficacy between entecavir and adefovir dipivoxil in hepatitis B e antigen-positive nucleos（t）ide-naive patients with chronic hepatitis B. Methods Chinese and English papers（randomized controlled clinical trials） about comparison of efficacy between entecavir and adefovir dipivoxil in hepatitis B e antigen-positive nucleos（t）ide-naive patients with chronic hepatitis B were searched from January 2003 to May 2010 online. Heterogeneity was examined by Chi-square test，the relative risk was calculated and forest-graph was drawn. The evaluated index contained undetectable serum HBV DNA，serum ALT normalization and HBeAg loss. Results 212 articles were totally found，and only one English and three Chinese articles fit well for the study were included. Meta analysis showed that the rates of undetectable serum HBV DNA（P=0.0002，RR=1.74）and serum ALT normalization（P=0.04，RR=1.34）in entecavir-treated patients at week 12 were higher than those in adefovir dipivoxil-treated，but there was no statistic significances as respect to the rates of undetectable serum HBV DNA （P=0.20） and HBeAg loss（P=0.27）between the two groups at week 24. Conclusion Entecavir has a quicker effect in decreasing serum HBV DNA and normalizing serum ALT at early stage than adefovir dipivoxil，however，the efficacies are the same at week 24.

Key words: Hepatitis B, HBeAg positive, Entecavir, Adefovir dipivoxil